ALT

Altimmune Inc

Altimmune, Inc. (NASDAQ:ALT - Free Report) - Analysts at HC Wainwright boosted their FY2025 earnings per share estimates for shares of Altimmune in a research note issued to investors on Tuesday...

Altimmune (NASDAQ:ALT - Get Free Report) announced its earnings results on Thursday. The company reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29...

Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT Altimmune, Inc. Securities Fraud Class Action Lawsuit...

ALT readies Q2 report as investors await fresh updates on pemvidutide program in obesity and liver disease studies.

Up to 59.1% patients enrolled in the study achieved metabolic dysfunction-associated steatohepatitis resolution without worsening of fibrosis at 24 weeks, as compared to merely 19.1% for placebo.

Traders are closely watching Thursday’s topline data for signs that pemvidutide could emerge as a competitive treatment in the growing MASH landscape.

In the second quarter, the firm expects to announce data from a phase 2 trial of its investigational therapy, Pemvidutide, in treating metabolic dysfunction-associated steatohepatitis (MASH).

A Betaville report suggested Altimmune has begun a strategic review with an adviser, with speculation that three major pharmaceutical firms may be involved.